IRIS

Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC-III melanoma. The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAFV600 mutation-positive melanoma.

Maio, M., Lewis, K., Demidov, L., Mandala, M., Bondarenko, I., Ascierto, P.a., et al. (2018). Adjuvant vemurafenib in resected, BRAFV600mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. THE LANCET ONCOLOGY, 19(4), 510-520 [10.1016/S1470-2045(18)30106-2].

Adjuvant vemurafenib in resected, BRAFV600mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Herbert C.;Bianchi L.;
2018-01-01

Abstract

Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC-III melanoma. The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAFV600 mutation-positive melanoma.
2018
Online ahead of print
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
Maio, M., Lewis, K., Demidov, L., Mandala, M., Bondarenko, I., Ascierto, P.a., et al. (2018). Adjuvant vemurafenib in resected, BRAFV600mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. THE LANCET ONCOLOGY, 19(4), 510-520 [10.1016/S1470-2045(18)30106-2].
Maio, M; Lewis, K; Demidov, L; Mandala, M; Bondarenko, I; Ascierto, Pa; Herbert, C; Mackiewicz, A; Rutkowski, P; Guminski, A; Goodman, Gr; Simmons, B; Ye, C; Yan, Y; Schadendorf, D; Cinat, G; Fein, Le; Brown, M; Guminski, A; Haydon, A; Khattak, A; Mcneil, C; Parente, P; Power, J; Roberts-Thomson, R; Sandhu, S; Underhill, C; Varma, S; Berger, T; Awada, A; Blockx, N; Buyse, V; Mebis, J; Franke, Fa; Jobim de Azevedo, S; Silva Lazaretti, N; Jamal, R; Mihalcioiu, C; Petrella, T; Savage, K; Song, X; Wong, R; Dabelic, N; Plestina, S; Vojnovic, Z; Arenberger, P; Kocak, I; Krajsova, I; Kubala, E; Melichar, B; Vantuchova, Y; Putnik, K; Dreno, B; Dutriaux, C; Grob, J-; Joly, P; Lacour, J-; Meyer, N; Mortier, L; Thomas, L; Fluck, M; Gambichler, T; Hassel, J; Hauschild, A; Schadendorf, D; Donnellan, P; Mccaffrey, J; Power, D; Ariad, S; Bar-Sela, G; Hendler, D; Ron, I; Schachter, J; Ascierto, P; Berruti, A; Bianchi, L; Chiarion Sileni, V; Cognetti, F; Danielli, R; Di Giacomo, Am; Gianni, L; Goldhirsch, A; Guida, M; Maio, M; Mandala, M; Marchetti, P; Queirolo, P; Santoro, A; Kapiteijn, E; Mackiewicz, A; Rutkowski, P; Ferreira, P; Demidov, L; Gafton, G; Makarova, Y; Andric, Z; Babovic, N; Jovanovic, D; Kandolf Sekulovic, L; Cohen, G; Dreosti, L; Vorobiof, D; Curiel Garcia, Mt; Diaz Beveridge, R; Majem Tarruella, M; Marquez Rodas, I; Puliats Rodriguez, J-; Rueda Dominguez, A; Maroti, M; Papworth, K; Michielin, O; Bondarenko, I; Brown, E; Corrie, P; Harries, M; Herbert, C; Kumar, S; Martin-Clavijo, A; Middleton, M; Patel, P; Talbot, T; Agarwala, S; Chapman, P; Conry, R; Doolittle, G; Gangadhar, T; Hallmeyer, S; Hamid, O; Hernandez-Aya, L; Johnson, D; Kass, F; Kolevska, T; Lewis, K; Lunin, S; Salama, A; Sikic, B; Somer, B; Spigel, D; Whitman, E
Articolo su rivista
01 - Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
maio2018.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 338 kB
Formato Adobe PDF
  Visualizza/Apri   Richiedi una copia
338 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/201579
Citazioni
  • ???jsp.display-item.citation.pmc??? 45
  • Scopus 161
  • ???jsp.display-item.citation.isi??? 146
social impact